Boston-based Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has announced significant amendments to its corporate charter, including a reverse stock split, as per a filing with the Securities and Exchange Commission (SEC) today. The biotech firm, specializing in biological engineering, has executed a one-for-forty reverse stock split of its Class A, Class B, and Class C common stock, effective immediately.
This strategic move aims to consolidate shares and potentially boost the stock's market price, making it more appealing to investors. Additionally, the company has introduced provisions for officer exculpation in its amended charter, offering legal protection to its officers against certain types of lawsuits, which could be a step towards aligning with corporate governance standards and attracting experienced executives.
The amendments also include the removal of provisions related to Ginkgo Bioworks' past merger with Soaring Eagle Acquisition Corp. and the domestication process that followed, streamlining the charter to better reflect the company's current operations and structure.
Ginkgo Bioworks' decision to revise its corporate charter and implement a reverse stock split follows a trend among companies looking to optimize their capital structure and governance in response to market conditions and corporate objectives.
In other recent news, Ginkgo Bioworks Holdings, Inc. shareholders have approved a reverse stock split at a ratio of one-for-forty. This decision, which received significant support, will consolidate every forty shares of the company's issued and outstanding common stock into one share. Additionally, the Officer Exculpation Proposal and the Charter Updates Proposal were also approved by shareholders.
On the financial front, Ginkgo Bioworks reported a decrease in cell engineering revenue to $36 million, a 20% drop from the previous year, while biosecurity revenue stood at $20 million with a 41% gross margin.
Despite the decline, the company reaffirmed its full-year guidance, expecting cell engineering revenue between $120 million to $140 million. As part of its strategic adjustments, the company is implementing cost reduction strategies, anticipating over $85 million in annualized savings.
In the wake of these developments, BTIG maintained its Sell rating on shares of Ginkgo Bioworks, with a steady stock target. The firm's stance comes after Ginkgo announced a significant workforce reduction, aiming for adjusted EBITDA breakeven by the end of 2026. BTIG expressed concern regarding the potential for Ginkgo's new initiative, lab data as a service (LDaaS), to generate lower economic returns compared to the company's traditional cell programs.
InvestingPro Insights
In light of Ginkgo Bioworks Holdings, Inc.'s recent corporate amendments and stock restructuring, current market data from InvestingPro offers a snapshot of the company's financial health and stock performance. With a market capitalization of $519.22 million, Ginkgo Bioworks holds a notable position in the biotech industry. However, the company's financials show significant challenges, with a negative P/E ratio of -0.51, indicating that it is not currently profitable. Additionally, the company's revenue has declined by 43.45% over the last twelve months as of Q2 2024, reflecting the competitive and dynamic nature of the biotech sector. Despite these hurdles, the firm's gross profit margin remains high at 80.22%, suggesting that while revenue is down, the cost of goods sold is being managed efficiently.
InvestingPro Tips highlight that Ginkgo Bioworks holds more cash than debt on its balance sheet, which is a positive sign of liquidity and financial stability. However, analysts are concerned about the company's cash burn rate and do not anticipate profitability for the current year. The stock has also experienced a significant downturn, with price total returns plummeting by 86.33% over the last year. For investors seeking a deeper analysis, InvestingPro offers an array of additional tips, providing a more comprehensive understanding of Ginkgo Bioworks' financial and market position.
For those interested in Ginkgo Bioworks' future prospects, it's worth noting that the company does not pay a dividend, which may influence investment decisions for income-focused shareholders. The InvestingPro platform lists several more tips for investors considering this stock, which can be accessed for a more detailed investment analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.